[ F]AV-1451 Tau Positron Emission Tomography in Progressive Supranuclear Palsy

Overview

Journal Mov Disord

Date 2016 Oct 28

PMID 27787958

Citations 88

Authors

Jennifer L Whitwell

Val J Lowe

Nirubol Tosakulwong

Stephen D Weigand

Matthew L Senjem

Christopher G Schwarz

Anthony J Spychalla

Ronald C Petersen

Clifford R Jack Jr

Keith A Josephs

Affiliations

Soon will be listed here.

Abstract

Background: The [ F]AV-1451 positron emission tomography ligand allows the in vivo assessment of tau proteins in the brain. It shows strong binding in Alzheimer's dementia, but little is known about how it performs in progressive supranuclear palsy, a primary 4R tauopathy.

Objectives: The objectives of this study were to determine whether [ F]AV-1451 uptake can be observed in progressive supranuclear palsy and to characterize the regional distribution when compared with controls and Alzheimer's dementia.

Methods: [ F]AV-1451 positron emission tomography was performed in 10 patients with probable progressive supranuclear palsy. These patients were age- and gender-matched to 50 controls and 10 Alzheimer's dementia patients who had undergone identical [ F]AV-1451 imaging. Regional comparisons of [ F]AV-1451 uptake were performed across the whole brain using region-of-interest and voxel-level analyses, and correlations between regional [ F]AV-1451 and the progressive supranuclear palsy rating scale were assessed.

Results: An elevated [ F]AV-1451 signal was observed in progressive supranuclear palsy when compared with controls in the pallidum, midbrain, dentate nucleus of the cerebellum, thalamus, caudate nucleus, and frontal regions. Signal in the cerebellar dentate and pallidum were also greater in progressive supranuclear palsy when compared with Alzheimer's dementia. Conversely, the [ F]AV-1451 signal across the cortex was higher in Alzheimer's dementia when compared with progressive supranuclear palsy. The [ F]AV-1451 signal in a number of regions correlated with the progressive supranuclear palsy rating scale.

Conclusions: Progressive supranuclear palsy is associated with an elevated [ F]AV-1451 signal in a characteristic and distinct regional pattern that correlates with disease severity and differs from the patterns observed in Alzheimer's dementia. © 2016 International Parkinson and Movement Disorder Society.

Citing Articles

Brainstem and cerebellar radiological findings in progressive supranuclear palsy.

Spiegel C, Marotta C, Bertram K, Vivash L, Harding I Brain Commun. 2025; 7(1):fcaf051.

PMID: 39958262 PMC: 11829206. DOI: 10.1093/braincomms/fcaf051.

Functional connectivity abnormalities in clinical variants of progressive supranuclear palsy.

Sintini I, Ali F, Stephens Y, Clark H, Stierwalt J, Machulda M Neuroimage Clin. 2024; 45:103727.

PMID: 39719808 PMC: 11728076. DOI: 10.1016/j.nicl.2024.103727.

Microscopy assessment of a fluorescence [F] flortaucipir analog (T726) shows neuropathological overlap with 3R and 4R tau lesions.

Gatto R, Hossam Y, Ross Reichard R, Lowe V, Whitwell J, Josephs K Alzheimers Dement. 2024; 20(12):8758-8768.

PMID: 39439289 PMC: 11667531. DOI: 10.1002/alz.14330.

Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.

Dilcher R, Wall S, Gross M, Katzdobler S, Wagemann O, Palleis C Alzheimers Dement. 2024; 20(10):6896-6909.

PMID: 39263969 PMC: 11485081. DOI: 10.1002/alz.14185.

The significance of cerebellar contributions in early-life through aging.

Verpeut J, Oostland M Front Comput Neurosci. 2024; 18:1449364.

PMID: 39258107 PMC: 11384999. DOI: 10.3389/fncom.2024.1449364.

References

Steele J, Richardson J, Olszewski J . PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol. 1964; 10:333-59. DOI: 10.1001/archneur.1964.00460160003001. View

Whitwell J, Master A, Avula R, Kantarci K, Eggers S, Edmonson H . Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch Neurol. 2011; 68(6):753-60. PMC: 3401587. DOI: 10.1001/archneurol.2011.107. View

Dani M, Brooks D, Edison P . Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2015; 43(6):1139-50. PMC: 4844651. DOI: 10.1007/s00259-015-3231-2. View

Respondek G, Roeber S, Kretzschmar H, Troakes C, Al-Sarraj S, Gelpi E . Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord. 2013; 28(4):504-9. DOI: 10.1002/mds.25327. View

Vemuri P, Whitwell J, Kantarci K, Josephs K, Parisi J, Shiung M . Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage. 2008; 42(2):559-67. PMC: 3097053. DOI: 10.1016/j.neuroimage.2008.05.012. View

Johnson K, Schultz A, Betensky R, Becker J, Sepulcre J, Rentz D . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2015; 79(1):110-9. PMC: 4738026. DOI: 10.1002/ana.24546. View

Sander K, Lashley T, Gami P, Gendron T, Lythgoe M, Rohrer J . Characterization of tau positron emission tomography tracer [F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016; 12(11):1116-1124. DOI: 10.1016/j.jalz.2016.01.003. View

Golbe L, Ohman-Strickland P . A clinical rating scale for progressive supranuclear palsy. Brain. 2007; 130(Pt 6):1552-65. DOI: 10.1093/brain/awm032. View

Agosta F, Galantucci S, Svetel M, Lukic M, Copetti M, Davidovic K . Clinical, cognitive, and behavioural correlates of white matter damage in progressive supranuclear palsy. J Neurol. 2014; 261(5):913-24. DOI: 10.1007/s00415-014-7301-3. View

10.

Xia C, Arteaga J, Chen G, Gangadharmath U, Gomez L, Kasi D . [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013; 9(6):666-76. DOI: 10.1016/j.jalz.2012.11.008. View

11.

Whitwell J, Avula R, Master A, Vemuri P, Senjem M, Jones D . Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. Parkinsonism Relat Disord. 2011; 17(8):599-605. PMC: 3168952. DOI: 10.1016/j.parkreldis.2011.05.013. View

12.

Hansen A, Knudsen K, Lillethorup T, Landau A, Parbo P, Fedorova T . In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. Brain. 2016; 139(Pt 7):2039-49. DOI: 10.1093/brain/aww098. View

13.

Meltzer C, Kinahan P, Greer P, Nichols T, Comtat C, Cantwell M . Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med. 2000; 40(12):2053-65. View

14.

Chien D, Bahri S, Szardenings A, Walsh J, Mu F, Su M . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2012; 34(2):457-68. DOI: 10.3233/JAD-122059. View

15.

Hauw J, Daniel S, Dickson D, Horoupian D, Jellinger K, Lantos P . Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994; 44(11):2015-9. DOI: 10.1212/wnl.44.11.2015. View

16.

Cho H, Choi J, Hwang M, Lee J, Kim Y, Lee H . Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016; 87(4):375-83. DOI: 10.1212/WNL.0000000000002892. View

17.

Lowe V, Curran G, Fang P, Liesinger A, Josephs K, Parisi J . An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016; 4(1):58. PMC: 4906968. DOI: 10.1186/s40478-016-0315-6. View

18.

Nasreddine Z, Phillips N, Bedirian V, Charbonneau S, Whitehead V, Collin I . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4):695-9. DOI: 10.1111/j.1532-5415.2005.53221.x. View

19.

Smith R, Puschmann A, Scholl M, Ohlsson T, Van Swieten J, Honer M . 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016; 139(Pt 9):2372-9. PMC: 4995360. DOI: 10.1093/brain/aww163. View

20.

McKhann G, Knopman D, Chertkow H, Hyman B, Jack Jr C, Kawas C . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):263-9. PMC: 3312024. DOI: 10.1016/j.jalz.2011.03.005. View